HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stada Arzneimittel AG

www.stada.de

Latest From Stada Arzneimittel AG

Generics Players Dominating New OTC Launches In Germany

An analysis by Sempora Consulting of the German OTC market in 2018 shows that generic products dominate new OTC product launches.
Health OTC Drugs

Stada ‘Continuously Evaluating’ OTC Deals As Sales Grow Double Digits

Stada tells HBW Insight it remains on the lookout for deals despite only last month closing the acquisition of a basket of OTC brands from GSK. The German firm revealed its plans as it reported a double-digit rise in both sales and earnings at its Branded Products business for the opening six months of 2019.
Business Strategies Sales & Earnings

Bortezomib Boom Benefits Stada But Pemetrexed Position Proves Perplexing

Launching the oncology drug bortezomib in 14 European countries helped Stada to record an 11% increase in both Generics and group sales in the first half of 2019. But the German group, which is about to start rolling out biosimilar teriparatide, has suffered a legal setback on pemetrexed in its home market.

Sales & Earnings Intellectual Property

Generics Players Dominating New OTC Launches In Germany

An analysis by Sempora Consulting of the German OTC market in 2018 shows that generic products dominate new OTC product launches.
Health OTC Drugs
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register